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Introduction: Fecal Lactoferrin (FL) is a timely and accurate marker of inflammation in 
ulcerative colitis (UC) and Crohn’s disease (CD).  Aim of this study was to verify whether 
FL can predict primary non-response (PNR) to biologic agents during induction. Methods: 
Retrospective outcome review in 27 patients (13 with CD and 14 with UC) tested for 
baseline FL and re-tested within a week after the first and second induction doses. 
Clinical/biochemical outcomes were evaluated at end of induction and at follow up (3-24 
months). Results: Compared to baseline, changes of the Harvey-Bradshaw (CD) and 
Partial Mayo Scoring (UC) indices at end of induction separated responders (18/27 or 
67%) from non-responders (9/17 or 33%).  In all patients the initial FL value at induction 
decreased compared to baseline, continuing to decrease after the following dose in 
clinical responders while bouncing back in the others. Models targeting the two 
consecutively decreased FL values or the second FL value compared to baseline or the 
second FL value compared to the first were able to accurately predict response at end of 
induction. Follow-up assessment confirmed clinical remission in initial responders (with 
FL values reduced on the average by 94±10% compared to baseline). Conclusions: In 
CD and UC patients during induction with biologic agents early FL measurements 
accurately separate clinical responders from those experiencing PNR. The method 
described here offers several potential advantages over other strategies to assess and 
manage these patients. 
 
Abbreviations: CD:Crohn’s Disease; UC: ulcerative colitis; IBD: inflammatory bowel 
disease; FL: fecal lactoferrin; FC: fecal calprotectin; TDM: therapeutic drug monitoring; 
TL: trough levels; ADA: anti-drug antibodies; PNR:  primary non response; LOR: loss of 
response; HBI: Harvey-Bradshaw Index; PMSI: Partial Mayo Scoring Index;  AUC: area 





Primary response to biologic induction in inflammatory bowel disease (IBD) – both 
ulcerative colitis (UC) and Crohn’s disease (CD) – has been traditionally evaluated by the 
attenuation of clinical symptoms after 12 weeks [1,2]. More recently, the measurement 
of drug trough levels (TL) and of anti drug antibodies (ADA) – a strategy known as 
Therapeutic Drug Monitoring (TDM) - has been used to evaluate possible loss of response 
[LOR] [3] and proposed by some to proactively reduce primary non-response [PNR] and 
LOR incidence [4-6].  Although pro-active TDM-based management might improve 
outcomes in IBD [4-6] this strategy is expensive and has practical shortcomings [7-11] 
and it is unclear whether it is truly superior to reactive TDM or to the clinically based 
management [12,13]. Ideally, it is the individual patient disease burden that should be 
targeted by therapy [14-16]. Fecal lactoferrin (FL) and calprotectin (FC) are accurate 
indicators of intestinal mucosa inflammation [17], but their role in the management of 
therapeutic response is still evolving [18]. A necessary feature of any strategy for the 
management of LOR and PNR is the test time-sensitivity i.e. the immediate 
responsiveness to drug-induced changes in mucosa inflammation.  We have published 
evidence that FC levels in IBD patients on biologics timely and sensibly reflect the 
increasing inflammatory activity during the therapeutic interval due to the progressive 
neutralization of the medication [19]. Indeed, fecal marker levels in stool are directly 
related to neutrophil translocation to the mucosa of the GI tract – a process quickly 
modulated by medications acting on the activity of the inflammatory process [20]. We 
have since leveraged on those findings to routinely evaluate the immediate response to 
treatment in patients undergoing biologic induction. In this retrospective study we report 








Study design and study population 
This retrospective study enrolled 27 consecutive patients with UC or CD diagnosed and 
staged according to established criteria [21], to be treated with biologic monotherapy 
(infliximab, adalimumab, certolizumab and vedolizumab) as standard of care in our IBD 
Center and enrolled within a two year period (2018-2020). No steroids or other 
medications were prescribed before the index FL tests and the end of induction. All 
patients tested negative for tuberculosis and hepatitis B and C as well as stool culture 
and C. difficile.  
FL levels as well as clinical/laboratory data were collected from the patients’ electronic 
medical records. Data collected involved patients (both naïve and biologic experienced) 
undergoing biologic induction. In these patients FL was measured at baseline (within one 
month of starting therapy) then within a week after drug administration for at least two 
consecutive infusions/injections during the induction phase (comprising 3 infusions for 
infliximab and vedolizumab [weeks 0-2-6], 2 injections for adalimumab [weeks 0-2] and 
3 injections for certolizumab [weeks 0-2-4]). Management of these patients was based 
on clinical outcomes and scores (see below) after completion of the induction phase. 
Follow up was 3 to 24 months - on the average 8 months - and included clinical and 
biochemical (post induction FL levels) assessment. 
Biomarker testing 
FL was measured in samples collected during the first bowel movement of the day by the 
LACTOFERRIN SCAN (TECHLAB, Blacksburg, VA), an enzyme-linked immunosorbent 
assay. Values ≤7.24 µg/mL are considered normal [22]. At Carilion Clinic Laboratory the 
lower limit to which the linearity of results has been validated is 6.25 µg/mL – which is 
the absolute value reported and analyzed for results ≤6.25 µg/mL. FL values are 
presented by standard decimal approximations of the actual number by excess or defect. 
Routine blood and stool studies were performed using established methods.  
5 
 
Assessment of clinical disease activity 
Clinical assessment was performed during clinic visits at baseline, within a week of 
completing induction and at follow up and was based on the Harvey-Bradshaw Index 
(HBI) for CD and the Partial Mayo Scoring Index (PMSI) for UC [23]. For HBI, scores of 
<5, 5–7, 8–16, and >16 define remission, mild, moderate and severe disease activity. 
The same activities are defined by the scores of 0-1, 2-4, 4-6, 7-9 for PMSI. Clinical 
response in UC was defined as a decrease of ≥3 of the partial Mayo score [24] plus a 
decrease of at least 30% from the baseline score, accompanied by a decrease of ≥1 in 
the rectal bleeding scale or an absolute rectal bleeding score of 0 or 1 [25]. Response in 
CD was defined as a decrease of ≥3 of the HBI [26]. 
Statistical Analysis 
Patients were separated in two groups based on the post induction clinical response. To 
uniformly analyze HBI and PMSI these indices were re-scaled to be between 0 and 1 by 
dividing each score by the maximum value for each scale with the value of “16” used as 
the maximum value for the HBI since all the scores above 16 are considered severe (and 
16 was also the highest value of the HBI in the data set). Analysis of these rescaled HBI 
and PMSI before and after induction treatment was performed using a non-parametric 
sign test within each group due to non-normality of these values; a Mann-Whitney U test 
was used to compare baseline values.  We also used non-parametric Mann-Whitney U 
test to compare the baseline FL values and the initial FL drop in the two groups of 
patients. 
Various combinations of FL measures were used to predict whether an individual would 
respond clinically (based on the criteria outlined in the previous section) following the 
entire induction cycle. The first of these measures was a dichotomous measure where 
participants were labeled as FL responders if they experienced two consecutive drops in 
FL compared to their baseline measurement and labeled as FL non-responders if they did 
not. The remaining measures were all numeric measures of FL (generally based on % of 
baseline measure), including FL values following the first induction dose (as a percentage 
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of baseline values), FL values following the second induction dose (as a percentage of 
baseline values), the baseline FL measure itself (in raw units), and the difference between 
the first and the second FL values (as a percentage of the baseline value). 
Logistic regression models were used to examine the relationships of each of these 
predictors to the outcome of remission. For all models, AUC (AUC: area under the ROC 
curve [ROC: receiver operating characteristic]), accuracy, sensitivity, specificity and FL 
cutoff values were calculated.  
 
Results 
There were 27 patients who underwent biologic induction (Table 1) with 14/27 being 
biologic naïve. The median age was 51 years, 48% had CD (with approximately equally 
distributed ileal, ileocolonic and colonic disease) and 52% had UC (2/3 with pancolitis). 
In CD patients the disease was mostly nonstricturing/nonpenetrating.  
Of the 27 patients 18 (67%) responded clinically to induction with normalized clinical 
scores dropping from 0.71±0.16 to 0.05±0.06, (p<0.0001) (Table 2). In all cases the 
numerical value of both HBI and PMSI fell within the definition of remission. In 9/27 
(33%) patients normalized clinical scores remained unchanged after induction 
(0.79±0.19 vs 0.71±0.13, p=0.06). Baseline clinical score values were very similar among 
the two groups (p=0.28). Although FL substantially decreased (by up to 98% of baseline 
levels) in all patients after the first infusion/injection, subsequent FL levels further 
decreased (or stayed within normal values/did not increase) only in clinical responders 
during induction (Table 2). In clinical non-responders subsequent FL levels increased, in 
some cases reaching levels close or superior to baseline values (Table 2). The data for all 
patients are graphically reported in Fig.1. No changes in management were made in the 
first group of patients since they responded to induction. However, the patients in the 
second group continued to experience severe symptoms after induction and were re-
induced with other biologics or underwent surgery if they had failed multiple biologics.  
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The baseline FL values were greater in the non-responders group compared to responders 
(2221± 1910 vs 773±1054 µg/mL, p=0.02). Likewise, the initial FL drop was less on the 
average in the non-responders although the difference was not statistically significant 
(62±36% vs 83±16%, p=0.09).  
Diagnostic accuracy for FL in predicting clinical response was calculated for different 
models (see Methods). Using the drop in FL values after the first induction dose (as a 
percentage of the baseline FL) the area under the curve (AUC) associated with the 
receiver operating curve (ROC) is 0.710 with a 95% CI of 0.497 - 0.923 (Supplementary 
Fig. 1). The FL cutoff (probability of clinical response greater than 0.5) is 45.6% of 
baseline with sensitivity of 1 and 95% CI of 0.847-1 and specificity of 0.333 and 95% CI 
of 0.075-0.701. Using the drop in FL value after the second drug dose (as a percentage 
of baseline FL) the AUC is estimated to be 1 (Supplementary Fig. 2). In this case, the FL 
cutoff is 42.7% of baseline with a sensitivity of 1 (95% CI = 0.847, 1) and specificity of 
1 (95% CI = 0.717, 1). Baseline FL (µg/mL) was also able to predict clinical response at 
end of induction with AUC of 0.778 (95% CI  = 0.570-0.986) sensitivity of 0.762 (95% 
CI = 0.528,0.918), specificity of 0.444 (95% CI = 0.137, 0.788) and baseline FL cutoff 
of 2334.07 µg/mL (Supplementary Fig. 3). Using the change in FL value after the second 
drug dose compared to the value after the first drug dose the AUC is estimated to be 1 
with a sensitivity of 1 (95% CI = 0.847, 1) a specificity of 1 (95% CI = 0.717, 1) and a 
FL cutoff of 25% of baseline FL (Supplementary Fig. 4).Finally, using the two consecutive 
FL drops as a criterion to predict remission the AUC is estimated to be 1 with a sensitivity 
of 1 (95% CI = 0.847, 1) and a specificity of 1 (95% CI = 0.717, 1) (Supplementary Fig. 
5).  
Follow up data were available for all patients from a minimum of 3 months to a maximum 
of 24 months. All the patients in the first group remained in clinical remission (<5 for the 
Harvey-Bradshaw Index and 0-1  for the Partial Mayo Scoring Index) at follow up with 
clinical scores superimposable to those post-induction and FL levels (measured at the 
reported follow up times – Table 2 - within a week after drug administration) reduced on 
the average by 93.5±9.8% (67- 99.9) compared to baseline values. 
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By contrast, of the nine patients who did not respond to induction with rebounding FL, 
four were re-induced with new biologics (with three of them responding) while the others 
either underwent immediate surgery or are planning to undergo surgery due to previous 
or new multiple biologic failures.  
 
Discussion   
LOR and PNR to biologic agents represent an important and frequent event in IBD [1,2]. 
Symptomatic improvement after 12 weeks of initial biologic induction has been 
traditionally used to evaluate response to therapy [1,2]. More recently, proactive TDM 
has been proposed as a tool to optimize initial drug treatment in these patients [4-6]. 
With proactive TDM, target TL are stipulated before induction and – when measured and 
found sub-therapeutic (in the absence of ADA) during and after induction - the drug dose 
is progressively increased. A number of studies have indeed shown that this interesting 
strategy could reduce PNR incidence and improve long term outcomes [4-6].  However, 
solid evidence for routine clinical use is still lacking [12,13]. In addition, this strategy is 
expensive and has some practical shortcomings [7-9, 27] – in particular in the USA [11]. 
One of the issues with this strategy is the assumption that there is a universal therapeutic 
TL – that can be applied to all patients. However, establishing universal, practically useful 
therapeutic TL has been proven challenging since TL vary according to a number of 
factors (9), most importantly the individual disease burden [14]. Indeed, using a priori 
stipulated values, a substantial proportion of patients on biologics are either in remission 
with “sub-therapeutic” TL — or might experience PNR/LOR with “therapeutic” TL 
[7,9,14,16,19,27,28].  
A more practical approach to manage patients starting a biologic would be to evaluate 
whether the medication directly impacts the disease activity – i.e. whether it is effective 
in reducing inflammation in the individual patient. Fecal markers of inflammation (FL/FC) 
accurately reflect mucosa inflammation [17,29,30] and disease burden [20,31] in IBD. 
However, their optimal use in disease management remains unclear [18]. Previous data 
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obtained with FC [19] show that fecal markers timely mirror drug-mediated changes in 
inflammation since they directly reflect neutrophil translocation to the mucosa of the GI 
tract – a process quickly modulated by the activity of the inflammatory process [20]. 
Hence, fecal markers could potentially be used to immediately monitor biologic response 
in IBD. In our Center we have used this strategy over the years to assess patients with 
LOR to biologics and to monitor primary response during induction. We have reported 
here the data related to the latter group of patients.                                            
We show that in all patients undergoing induction the biologic agent induced an initial 
drop in FL compared to baseline levels. However, after the following dose, FL levels 
bounced back in approximately 30% of patients while keeping on decreasing (or remain 
low) in the others. Only in the latter patients clinical scores significantly dropped into the 
remission range at the end of induction. In the former group, the symptoms persisted 
and the medication was changed or patients underwent (or are planning) surgery if they 
had failed multiple biologics.  Follow up confirmed persistence of clinical remission (and 
FL levels reduced on the average by 94%) over time only in initial responders, all of 
whom had two consecutive decreased FL levels during induction. Of the unresponsive 
patients who changed medication, three out of four responded to new biologics while the 
others – due to multiple biologic failures - either underwent immediate surgery or are 
planning to undergo surgery. 
Logistic regression analysis showed that the two consecutively decreased FL values after 
the initial induction doses could predict remission at end of induction. When FL 
measurements were extended to the third induction dose, the patterns described above 
(continuous FL decrease vs initial decrease with subsequent rebound) did not appear to 
change in individual patients (D.Sorrentino, unpublished). Hence, testing patients only 
after the second and the third induction dose could be equally informative.  Models 
targeting single FL values (second FL value compared to baseline and second FL value 
compared to the first) were also able to predict remission. Models using the baseline FL 
or the FL drop after the first drug dose were less accurate in predicting remission.    
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Pavlidis et al. have also shown that early post-induction changes in FC predict PNR clinical 
outcomes in CD [32]. By contrast to us, those authors tested the fecal marker up to 10 
weeks after the first induction dose and only studied anti-TNF naïve patients, with more 
than half of them being on combination therapy. Similarly to us, DeVos et al. have shown 
that a constant and deep decrease in FC during and after induction predicts remission at 
week 10 in patients treated with infliximab [33]. Theede et al. tested for FC 16 patients 
with active UC being treated with steroids and showed that the stool markers dropped 
immediately in all patients and correlated well with clinical and biochemical parameters 
[34]. By contrast, Toyonaga et al [35] in 27 UC patients (mostly treated with steroids 
with a minority treated with anti-TNF agents or tacrolimus) showed that clinical scores 
dropped faster than FC levels, this possibly due to daily FC variability. In our study, as 
discussed above, 2 consecutive FL drops as well as single FL values during induction 
predicted the response to therapy. These findings are consistent with the traditional 
clinical approach whereby the lack of clinical improvement after two induction doses was 
considered an indication to switch therapy [1,2].   
The significant drop (up to 98%) in FL levels in all of our patients (including non-
responders) after the initial infusion/injection was somewhat unexpected. Billiet et al. 
have reported a similar phenomenon testing different cytokines [16].  It is possible that 
neutralizing antibodies produced after the first drug dose hamper response to the 
following drug administration [36].  However, it is also possible that inflammation 
switches to a different “driver” once a given pathway has been blocked by the medication 
in susceptible individuals [14,37]. It is also possible that patients with high inflammatory 
burden are more likely to experience PNR and might need a higher dose [16]. However, 
there is no clear evidence that initial induction doses might be insufficient in a proportion 
of patients due to a very high disease burden. Billiet et al suggested that some of the 
non-responders might have lower tissue concentrations of medication and that – by 
inference - higher doses could be effective [16]. In theory, it is possible that in our non-
responsive patients inflammation (and FL) increased after an initial drop due to the 
excessive consumption of medication because of the large disease burden. Indeed, 
11 
 
baseline FL levels were higher on the average in non-responsive patients. However, there 
was a large overlap among responders and non-responders and a number of patients 
with very high baseline FL levels did respond to the same medications/doses/therapeutic 
intervals used in non-responders.  
An additional issue partially addressed by our study relates to the concept that anti-
integrin therapies such as vedolizumab have a slow onset of action [38]. In our study 
there were both responders and non-responders among patients on vedolizumab, 
irrespective of their previous experience with biologics. Hence, our limited observations 
suggest that these medications might actually act as fast as any other biologic agent. 
Our study has some limitations. First of all, the sample size was relatively small and this 
might have affected our absolute remission rates and FL cut off values. Replication of this 
study by others and on a larger scale would clearly be important. Nevertheless, the basic 
findings of this study (the high accuracy of early stool marker measures to predict 
response after induction) are fully consistent with those of others [32-35].  
Also, our study is retrospective. In addition, we did not measure TL and ADA, which could 
have added interesting mechanistic information to our findings. A number of other issues 
are also worth a mention. First, adopting this fecal marker-based strategy might be 
challenging when the disease only involves a short small bowel segment and FL levels 
might [20] or might not [39] be elevated even in the absence of therapy. In general, 
detectable FL levels at baseline would be the only pre-requisite to apply this strategy. 
Second, FL should be measured at the same, fixed time after each drug administration 
since it tends to increase over time [19] – for example, values measured 1 day after drug 
administration would be lower than those measured 10 days after [19]. Finally, it is 
important to keep in mind that steroids or any other effective fast-acting medications 
given before/during induction and the double FL testing could affect the results. In our 
patients no concomitant medications were given in such period. If clinically needed (i.e. 
patient experiencing severe symptoms while waiting for induction) steroids could be 
initiated and kept on a stable dose well before and after induction – an approach that is 
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classically used in clinical trials. In such case, baseline FL values would be those measured 
before induction with the patient already on stable steroid therapy. 
In conclusion, the timely sensitivity of FL to drug-generated changes in inflammation 
provides the rationale for an accurate, rapid and inexpensive stool marker-based strategy 
to predict PNR in IBD patients undergoing induction with biologic agents.  We have 
recently shown that such fecal marker-based approach might also be applied to patients 
experiencing a potential loss of response to biologic agents [40].  However, larger 
prospective studies will be needed to evaluate the potential applicability of these 
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Figure 1. FL levels in IBD patients at baseline (before therapy) and during biologic 
induction. A: patients showing a progressive FL decrease. These patients showed clinical 
response after induction and continued to be in full remission at follow-up. B: patients 
showing an initial FL drop with a subsequent increase. These patient did not respond 
clinically to induction and therapy was changed to a different biologic or they underwent 
surgery. 
Supplementary Figure 1. ROC Curve for Predicting Clinical Response from Drop in FL 
Value after First Induction Dose (% of Baseline). 
Supplementary Figure 2. ROC Curve for Predicting Clinical Response from Drop in FL 
Value after Second Induction Dose (% of Baseline). 
Supplementary Figure 3. ROC Curve for Predicting Clinical Response from Baseline 
FL (µg/mL). 
Supplementary Figure 4. ROC Curve for Predicting Clinical Response from Change in 
FL Value Between First and Second Induction Dose (% of Baseline). 
Supplementary Figure 5. ROC Curve for Predicting Clinical Response from FL 




Table 1. Patient features  
Demographics N=27 
Age in years, median (IQR) 51 (32.5) 
Gender (Males – Females) 15 – 12 
Smoker (Current, former, never %) 18, 30, 52 
Disease Characteristics   
Disease Type    
     CD, N (%) 13 (48) 
     UC, N (%) 14 (52) 
Disease duration in years, median (IQR) 6 (8) 
Biologic naïve (yes/no) 14/13 
Biologic induction:      
     Infliximab, N (%) 15 (55) 
     Vedolizumab, N (%)   7 (30) 
     Adalimumab, N (%)   4 (15) 
     Certolizumab, N (%) 1 (4) 
CD Location (%)   
     L1: ileal 30 
     L2: colonic 30 
     L3: ileocolonic 40 
CD Behavior (%)   
     B1: nonstricturing, nonpenetrating 85 
     B2: stricturing 15 
     B3: penetrating 0 
UC Location (%)   
     E1: Ulcerative proctitis  15 
     E2: Left-sided (distal) 21 
     E3: Extensive (pancolitis) 64 
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     Follow-up, clinical 
    outcome (index) and 
 Fecal Lactoferrin 
(µg/mL) 
      Responders     
1 CD Yes 337 47  27  Infliximab 8 / 0 N/A None 
12 months. Clinical 
remission^ (0). 6.25 
 
2 CD Yes 4262 483  6.25  Infliximab 14 / 2 N/A None 
24 months. Clinical 
remission (0). 6.25 
 
3 UC No 1306 82  6.25  Infliximab N/A 6 / 0 None 
11 months. Clinical 
remission (1). 62 
 
4 CD Yes 68 6.25  6.25  Infliximab 13 / 0 N/A None 
10 months. Clinical 
remission (0). 6.25 
 
5 UC No 386 173 94  Infliximab N/A 9 / 1 None 
6 months. Clinical 
remission (0). 6.25 
 
6 UC No 753 283  15  Vedolizumab N/A 5 / 0 None 
12 months. Clinical 
remission (0). 6.25 
 
7 CD Yes 159 51  27  Adalimumab 8 / 2 N/A None 
12 months. Clinical 
remission (2). 23 
 
8 CD Yes 229 6.25  6.25  Infliximab 14 / 1 N/A None 
6 months. Clinical 
remission (1). 6.25 
 
9 UC Yes 454 6.25  6.25  Vedolizumab N/A 5 / 0 None 
 8 months. Clinical 
remission (0). 6.25 
 
 
10 CD No 43 6.25  6.25  Adalimumab 12 / 3 N/A None 
6 months. Clinical 




11 UC No 2585 44  32  Infliximab N/A 5 / 0 None 
9 months. Clinical 
remission (1). 65 
 
12 CD No 181 38  20  Infliximab 13 / 1 N/A None 
8 months. Clinical 
remission (2). 61 
 
 
13 CD Yes 819 23  14 Adalimumab 12 / 0 N/A None 
7 months. Clinical 
remission (0). 6.25 
 
14 CD No 597 77  8  Adalimumab 11 / 1 N/A None 
3 months. Clinical 
remission (0). 6.25 
 
15 CD  No 227 6.25  6.25  Infliximab 8 / 0 N/A None 
12 months. Clinical 
remission (0). 6.25 
 
16 UC Yes 673 299 280 Vedolizumab N/A 8/0 None 
6 months. Clinical 
remission (0). 7.3 
17 UC No 600 217 59 Infliximab N/A 8/1 None 
3 months. Clinical 
remission (0). 6.25 
18 CD     Yes         228         6.25 6.25 Infliximab 10/1 N/A None 
18 months. Clinical 
remission (0). 6.25 
           
      Non-responders     
19 UC No 1130 46  732  Vedolizumab N/A 5 / 5 
Therapy 
Change 
4 months. Failed 2 
more biologics (5). 
Considering surgery 




4 months. Surgical 
remission (1) 





6 months. Surgical 
remission (1) 






3 months. Currently     





*Infliximab and vedolizumab are administered as three induction infusions at weeks 0, 2, and 6, adalimumab as two injections at weeks 0 and 2 and Certolizumab 
as three injections at weeks 0, 2 and 4.  
 
 +Pre-post induction: before starting therapy and at the end of the induction          
                                   
^Clinical remission defined as a score <5 (Harvey-Bradshaw Index) or 0-1 (Partial Mayo Scoring Index)                           
N/A: Not applicable                 
                                    
 
23 UC Yes 277 248  386  Vedolizumab N/A 6 / 6 
Therapy 
Change 
     
 
  3 months. Currently 
in remission with 
Ustekinumab (1) 
 
24 UC No 3637 927  2805  Vedolizumab N/A 9 / 7 
Therapy 
Change 
 3 months. Currently 
in remission with 
Infliximab (1) 




7 months. Surgical 
remission (2) 
26 CD Yes 936 151 442 Certolizumab  12/10 N/A - 
 
3 months. (9) 
Considering surgery 
 
27 UC Yes 2700 433 2447 Vedolizumab N/A 6/6 - 
 
3 months.  (5). 
Surgery scheduled 
           






